Diuretic treatment using the RenalGuard® system in patients hospitalized due to acute decompensated heart failure and characterization of the profile of patients with good and poor response to treatment — preliminary study
Abstract
Background: The aim of the study was to analyze the potential relationship between the diuretic response, the clinical profile and the concentrations of selected biochemical markers and to identify a group of patients who will benefit from a new form of therapy combining standard diuretic therapy with the use of a RenalGuard® system.
Methods: This is a retrospective study of 19 patients (mean age 67 ± 10 years, 95% men) hospitalized due to acute decompensated heart failure (ADHF, NYHA class III–IV, BP 125 ± 14/73 ± 16 mmHg, eGFR 58 ± 24) with persistent overhydration despite standard therapy. A targeted comparative analysis of selected clinical and biochemical parameters was performed to determine the parameters associated with a better diuretic response [good diuretic responders (GDR) group].
Results: The good diuretic responders group had significantly lower levels of creatinine (1.23 ± 0.4 vs. 1.69 ± 0.35, p = 0.025) magnesium 0.70 ± 0.14 vs. 0.83 ± 0.09, p = 0.030) and blood urea nitrogen (BUN, 28 ± 11 vs. 39 ± 10, p = 0.045). Additionally, in GDR group a statistically significant greater ability to dilute urine in the 12th and 24th hour of therapy was found.
Conclusions: The results of the study indicate the potential use of the RenalGuard® system in combination with standard intravenous diuretic therapy for controlled dehydration in the treatment of a selected group of patients with ADHF. It is advisable to identify the detailed mechanisms of GDR and characterize this group of patients more precisely.
Keywords: acute heart failuredecongestiondiuretic responsespot urine analysisbiomarkers
References
- McDonagh TA, Metra M, Adamo M, et al. ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021; 42(36): 3599–3726.
- Shah MR, Hasselblad V, Stinnett SS, et al. Hemodynamic profiles of advanced heart failure: association with clinical characteristics and long-term outcomes. J Card Fail. 2001; 7(2): 105–113.
- Mentz R, Kjeldsen K, Rossi G, et al. Decongestion in acute heart failure. Eur J Heart Fail. 2014; 16(5): 471–482.
- Mullens W, Damman K, Harjola V, et al. The use of diuretics in heart failure with congestion — a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019; 21(2): 137–155.
- Filippatos G, Angermann CE, Cleland JGF, et al. Global differences in characteristics, precipitants, and initial management of patients presenting with acute heart failure. JAMA Cardiol. 2020; 5(4): 401–410.
- Cleland JGF, Coletta A, Witte K. Practical applications of intravenous diuretic therapy in decompensated heart failure. Am J Med. 2006; 119(12): S26–S36.
- Cox ZL, Rao VS, Ivey-Miranda JB, et al. Compensatory post-diuretic renal sodium reabsorption is not a dominant mechanism of diuretic resistance in acute heart failure. Eur Heart J. 2021; 42(43): 4468–4477.
- Verdiani V, Lastrucci V, Nozzoli C. Worsening renal function in patients hospitalized with acute heart failure: risk factors and prognostic significances. Int J Nephrol. 2010; 2011(785974).
- Levi TM, Rocha MS, Almeida DN, et al. Furosemide is associated with acute kidney injury in critically ill patients. Braz J Med Biol Res. 2012; 45(9): 827–833.
- Chioncel O, Mebazaa A, Harjola VP, et al. Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC heart failure long-term registry. Eur J Heart Fail. 2017(10): 1242–1254.
- Costanzo MR, Saltzberg M, O'Sullivan J, et al. Early ultrafiltration in patients with decompensated heart failure and diuretic resistance. J Am Coll Cardiol. 2005; 46(11): 2047–2051.
- Bart BA, Boyle A, Bank AJ, et al. Ultrafiltration versus usual care for hospitalized patients with heart failure: the relief for acutely fluid-overloaded patients with decompensated congestive heart failure (RAPID-CHF) trial. J Am Coll Cardiol. 2005; 46(11): 2043–2046.
- Costanzo MR, Guglin ME, Saltzberg MT, et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol. 2007; 49(6): 675–683.
- Bart BA, Goldsmith SR, Lee KL, et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med. 2012; 367(24): 2296–2304.
- Vazir A, Simpkin VL, Marino P, et al. Association of haemodynamic changes measured by serial central venous saturation during ultrafiltration for acutely decompensated heart failure with diuretic resistance and change in renal function. Int J Cardiol. 2016; 220: 618–622.
- Briguori C, Visconti G, Focaccio A, et al. Renal insufficiency after contrast media administration trial II (REMEDIAL II): renalguard system in high-risk patients for contrast-induced acute kidney injury. Circulation. 2011; 124(11): 1260–1269.
- Marenzi G, Ferrari C, Marana I, et al. Prevention of contrast nephropathy by furosemide with matched hydration: the MYTHOS (induced diuresis with matched hydration compared to standard hydration for contrast induced nephropathy prevention) trial. JACC Cardiovasc Interv. 2012; 5(1): 90–97.
- Mattathil S, Ghumman S, Weinerman J, et al. Use of the RenalGuard system to prevent contrast-induced AKI: a meta-analysis. J Interv Cardiol. 2017; 30(5): 480–487.
- Luckraz H, Giri R, Wrigley B, et al. Reduction in acute kidney injury post cardiac surgery using balanced forced diuresis: a randomized, controlled trial. Eur J Cardiothorac Surg. 2021; 59(3): 562–569.
- Biegus J, Zymlinski R, Siwolowski P, et al. Controlled decongestion by reprieve therapy in acute heart failure: results of the TARGET-1 and TARGET-2 studies. Eur J Heart Fail. 2019; 21(9): 1079–1087.
- Rosano G, Moura B, Metra M, et al. Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2021; 23(6): 872–881.
- Zandijk A, Norel Mv, Julius F, et al. Chloride in heart failure: the neglected electrolyte. JACC Heart Fail. 2021; 9(12): 904–915.
- Kataoka H. Chloride in heart failure syndrome: its pathophysiologic role and therapeutic implication. Cardiol Ther. 2021; 10(2): 407–428.
- Biegus J, Zymliński R, Testani J, et al. Renal profiling based on estimated glomerular filtration rate and spot urine sodium identifies high-risk acute heart failure patients. Eur J Heart Fail. 2021; 23(5): 729–739.
- Nawrocka-Millward S, Biegus J, Fudim M, et al. The role of urine chloride in acute heart failure. Sci Rep. 2024; 14(1): 14100.
- Iwanek G, Guzik M, Zymliński R, et al. Spot urine sodium-to-creatinine ratio surpasses sodium in identifying poor diuretic response in acute heart failure. ESC Heart Fail. 2024; 11(5): 3438–3442.
- Guzik M, Iwanek G, Fudim M, et al. Spot urine sodium as a marker of urine dilution and decongestive abilities in acute heart failure. Sci Rep. 2024; 14(1): 1494.
